{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T13:11:37Z","timestamp":1791810697790,"version":"4.3.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T00:00:00Z","timestamp":1731024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"DOI":"10.1186\/s13075-024-03431-5","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T04:52:01Z","timestamp":1731041521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Timely escalation to second-line therapies after failure of methotrexate in patients with early rheumatoid arthritis does not reduce the risk of becoming difficult-to-treat"],"prefix":"10.1186","volume":"26","author":[{"given":"Bernardo","family":"D\u2019Onofrio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludovico","family":"De Stefano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Bozzalla Cassione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Morandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cuzzocrea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garifallia","family":"Sakellariou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Manzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlomaurizio","family":"Montecucco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5396-7077","authenticated-orcid":false,"given":"Serena","family":"Bugatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,8]]},"reference":[{"key":"3431_CR1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","volume":"82","author":"JS Smolen","year":"2023","unstructured":"Smolen JS, Landew\u00e9 RBM, Bergstra SA, Kerschbaumer A, Sepriano A, Aletaha D, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023;82:3\u201318. https:\/\/doi.org\/10.1136\/ard-2022-223356.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR2","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1093\/rheumatology\/kex349","volume":"57","author":"MJH de Hair","year":"2018","unstructured":"de Hair MJH, Jacobs JWG, Schoneveld JLM, van Laar JM. Difficult-to-treat rheumatoid arthritis: an area of unmet clinical need. Rheumatology (Oxford). 2018;57:1135\u201344. https:\/\/doi.org\/10.1093\/rheumatology\/kex349.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR3","doi-asserted-by":"publisher","first-page":"e002387","DOI":"10.1136\/rmdopen-2022-002387","volume":"8","author":"Y Tan","year":"2022","unstructured":"Tan Y, Buch MH. Difficult to treat\u2019 rheumatoid arthritis: current position and considerations for next steps. RMD Open. 2022;8:e002387. https:\/\/doi.org\/10.1136\/rmdopen-2022-002387.","journal-title":"RMD Open"},{"key":"3431_CR4","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1136\/annrheumdis-2017-212862","volume":"77","author":"MH Buch","year":"2018","unstructured":"Buch MH. Defining refractory rheumatoid arthritis. Ann Rheum Dis. 2018;77:966\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212862.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NMT, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al. EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021;80:31\u20135. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR6","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","volume":"60","author":"S Takanashi","year":"2021","unstructured":"Takanashi S, Kaneko Y, Takeuchi T. Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice. Rheumatology (Oxford). 2021;60:5247\u201356. https:\/\/doi.org\/10.1093\/rheumatology\/keab209.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/art.42767","volume":"76","author":"P David","year":"2024","unstructured":"David P, Di Matteo A, Hen O, Dass S, Marzo-Ortega H, Wakefield RJ, et al. Poly-refractory rheumatoid arthritis: an uncommon subset of difficult to treat Disease with distinct inflammatory and noninflammatory phenotypes. Arthritis Rheumatol. 2024;76:510\u201321. https:\/\/doi.org\/10.1002\/art.42767.","journal-title":"Arthritis Rheumatol"},{"key":"3431_CR8","doi-asserted-by":"publisher","first-page":"e003808","DOI":"10.1136\/rmdopen-2023-003808","volume":"10","author":"A Bertsias","year":"2024","unstructured":"Bertsias A, Flouri ID, Repa A, Avgoustidis N, Kalogiannaki E, Pitsigavdaki S, et al. Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with \u2018difficult to treat\u2019 rheumatoid arthritis. RMD Open. 2024;10:e003808. https:\/\/doi.org\/10.1136\/rmdopen-2023-003808.","journal-title":"RMD Open"},{"key":"3431_CR9","doi-asserted-by":"publisher","first-page":"152421","DOI":"10.1016\/j.semarthrit.2024.152421","volume":"66","author":"GC McDermott","year":"2024","unstructured":"McDermott GC, DiIorio M, Kawano Y, Jeffway M, MacVicar M, Dahal K, et al. Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis. Semin Arthritis Rheum. 2024;66:152421. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152421.","journal-title":"Semin Arthritis Rheum"},{"key":"3431_CR10","doi-asserted-by":"publisher","unstructured":"Watanabe R, Ebina K, Gon T, Okano T, Murata K, Murakami K, et al. Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology (Oxford). 2024;May 9(keae265). https:\/\/doi.org\/10.1093\/rheumatology\/keae265.","DOI":"10.1093\/rheumatology\/keae265"},{"key":"3431_CR11","doi-asserted-by":"publisher","unstructured":"Paudel ML, Li R, Naik C, Shadick N, Weinblatt ME, Solomon DH. Prevalence and characteristics of adults with difficult-to-treat rheumatoid arthritis in a large patient Registry. Rheumatol (Oxford) 2024 Jun 5:keae318. https:\/\/doi.org\/10.1093\/rheumatology\/keae318","DOI":"10.1093\/rheumatology\/keae318"},{"key":"3431_CR12","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.rdc.2019.07.001","volume":"45","author":"JS Smolen","year":"2019","unstructured":"Smolen JS. Treat to target in Rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin North Am. 2019;45:477\u201385. https:\/\/doi.org\/10.1016\/j.rdc.2019.07.001.","journal-title":"Rheum Dis Clin North Am"},{"key":"3431_CR13","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.autrev.2011.10.019","volume":"11","author":"I Olivieri","year":"2012","unstructured":"Olivieri I, Sarzi-Puttini P, Bugatti S, Atzeni F, d\u2019Angelo S, Caporali R. Early treatment in early undifferentiated arthritis. Autoimmun Rev. 2012;11:589\u201392. https:\/\/doi.org\/10.1016\/j.autrev.2011.10.019.","journal-title":"Autoimmun Rev"},{"issue":"12","key":"3431_CR14","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1136\/annrheumdis-2018-214918","volume":"78","author":"D Aletaha","year":"2019","unstructured":"Aletaha D, Maa JF, Chen S, Park SH, Nicholls D, Florentinus S, Furtner D, Smolen JS. Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2019;78(12):1609\u201315.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.semarthrit.2010.03.003","volume":"40","author":"JR Curtis","year":"2010","unstructured":"Curtis JR, Jain A, Askling J, Bridges SL Jr, Carmona L, Dixon W, et al. A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registries. Semin Arthritis Rheum. 2010;40:2\u2013e141. https:\/\/doi.org\/10.1016\/j.semarthrit.2010.03.003.","journal-title":"Semin Arthritis Rheum"},{"key":"3431_CR16","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1093\/rheumatology\/keu446","volume":"54","author":"L Kearsley-Fleet","year":"2015","unstructured":"Kearsley-Fleet L, Z\u00e1vada J, Hetland ML, Nordstr\u00f6m DC, Aaltonen KJ, Listing J, et al. The EULAR Study Group for Registers and Observational Drug Studies: comparability of the patient case mix in the European biologic disease modifying anti-rheumatic drug registers. Rheumatology (Oxford). 2015;54:1074\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keu446.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR17","doi-asserted-by":"publisher","first-page":"151979","DOI":"10.1016\/j.semarthrit.2022.151979","volume":"53","author":"A Egeberg","year":"2022","unstructured":"Egeberg A, Rosen\u00f8 NAL, Aagaard D, L\u00f8rup EH, Nielsen ML, Nymand L, et al. Drug survival of biologics and novel immunomodulators for rheumatoid arthritis, axial spondyloarthritis, psoriatic arthritis, and psoriasis - A nationwide cohort study from the DANBIO and DERMBIO registries. Semin Arthritis Rheum. 2022;53:151979. https:\/\/doi.org\/10.1016\/j.semarthrit.2022.151979.","journal-title":"Semin Arthritis Rheum"},{"key":"3431_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13075-024-03287-9","volume":"26","author":"J Calvo-Guti\u00e9rrez","year":"2024","unstructured":"Calvo-Guti\u00e9rrez J, L\u00f3pez-Medina C, Otero-Varela L, Escudero-Contreras A, Ortega-Castro R, Ladehesa-Pineda L, et al. Impact of multimorbidity on the first ts\/bDMARD effectiveness and retention rate after two years of follow-up in patients with rheumatoid arthritis from the BIOBADASER registry. Arthritis Res Ther. 2024;26:57. https:\/\/doi.org\/10.1186\/s13075-024-03287-9.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"3431_CR19","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1186\/s13075-022-02824-8","volume":"24","author":"G Sakellariou","year":"2022","unstructured":"Sakellariou G, Scir\u00e8 CA, Rumi F, Carrara G, Zanetti A, Cerra C, et al. Influence of initial glucocorticoid co-medication on mortality and hospitalization in early inflammatory arthritis: an investigation by record linkage of clinical and administrative databases. Arthritis Res Ther. 2022;24(1):144. https:\/\/doi.org\/10.1186\/s13075-022-02824-8.","journal-title":"Arthritis Res Ther"},{"key":"3431_CR20","first-page":"401","volume":"35","author":"S Balduzzi","year":"2017","unstructured":"Balduzzi S, Scir\u00e8 CA, Sakellariou G, Benaglio F, Bugatti S, Montecucco C, et al. In early inflammatory polyarthritis more intensive management according to the 2010 ACR\/EULAR criteria leads to higher rates of clinical remission: comparison of two cohorts treated according to different treat-to-target protocols. Clin Exp Rheumatol. 2017;35:401\u20135.","journal-title":"Clin Exp Rheumatol"},{"key":"3431_CR21","doi-asserted-by":"publisher","first-page":"1759720X2110118","DOI":"10.1177\/1759720X211011826","volume":"13","author":"S Bugatti","year":"2021","unstructured":"Bugatti S, De Stefano L, Manzo A, Sakellariou G, Xoxi B, Montecucco C. Limiting factors to boolean remission differ between autoantibody-positive and -negative patients in early rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211011826. https:\/\/doi.org\/10.1177\/1759720X211011826.","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"3431_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"FC Arnett","year":"1988","unstructured":"Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315\u201324. https:\/\/doi.org\/10.1002\/art.1780310302.","journal-title":"Arthritis Rheum"},{"key":"3431_CR23","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League against Rheumatism collaborative initiative. Ann Rheum Dis. 2010;69:1580\u20138. https:\/\/doi.org\/10.1136\/ard.2010.138461.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR24","first-page":"743","volume":"26","author":"D van der Heijde","year":"1999","unstructured":"van der Heijde D. How to read radiographs according to the Sharp\/van Der Heijde method. J Rheumatol. 1999;26:743\u20135.","journal-title":"J Rheumatol"},{"key":"3431_CR25","doi-asserted-by":"publisher","first-page":"3866","DOI":"10.1093\/rheumatology\/kead143","volume":"62","author":"S Hecquet","year":"2023","unstructured":"Hecquet S, Combier A, Steelandt A, Pons M, Wendling D, Molto A, et al. Characteristics of patients with difficult-to-treat rheumatoid arthritis in a French single-centre hospital. Rheumatology (Oxford). 2023;62:3866\u201374. https:\/\/doi.org\/10.1093\/rheumatology\/kead143.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR26","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1186\/s13075-015-0716-0","volume":"17","author":"G Haugeberg","year":"2015","unstructured":"Haugeberg G, Hansen IJ, Soldal DM, Sokka T. Ten years of change in clinical disease status and treatment in rheumatoid arthritis: results based on standardized monitoring of patients in an ordinary outpatient clinic in southern Norway. Arthritis Res Ther. 2015;17:219. https:\/\/doi.org\/10.1186\/s13075-015-0716-0.","journal-title":"Arthritis Res Ther"},{"key":"3431_CR27","doi-asserted-by":"publisher","first-page":"e1003296","DOI":"10.1371\/journal.pmed.1003296","volume":"17","author":"XME Matthijssen","year":"2020","unstructured":"Matthijssen XME, Niemantsverdriet E, Huizinga TWJ, van der Helm-van Mil AHM. Enhanced treatment strategies and distinct disease outcomes among autoantibody-positive and -negative rheumatoid arthritis patients over 25 years: a longitudinal cohort study in the Netherlands. PLoS Med. 2020;17:e1003296. https:\/\/doi.org\/10.1371\/journal.pmed.1003296.","journal-title":"PLoS Med"},{"key":"3431_CR28","doi-asserted-by":"publisher","first-page":"5073","DOI":"10.1093\/rheumatology\/keab398","volume":"60","author":"B Combe","year":"2021","unstructured":"Combe B, Rincheval N, Berenbaum F, Boumier P, Cantagrel A, Dieude P, et al. Current favourable 10-year outcome of patients with early rheumatoid arthritis: data from the ESPOIR cohort. Rheumatology (Oxford). 2021;60:5073\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keab398.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR29","doi-asserted-by":"publisher","first-page":"105060","DOI":"10.1016\/j.jbspin.2020.07.009","volume":"88","author":"J Kedra","year":"2021","unstructured":"Kedra J, Granger B, Emilie S, Gaujoux-Viala C, Rat AC, Combe B, et al. Time to initiation of biologic disease-modifying antirheumatic drugs in the French cohort ESPOIR. Joint Bone Spine. 2021;88:105060. https:\/\/doi.org\/10.1016\/j.jbspin.2020.07.009.","journal-title":"Joint Bone Spine"},{"key":"3431_CR30","doi-asserted-by":"publisher","first-page":"e003027","DOI":"10.1136\/rmdopen-2023-003027","volume":"9","author":"H Westerlind","year":"2023","unstructured":"Westerlind H, Glintborg B, Hammer HB, Saevarsdottir S, Krogh NS, Hetland ML, et al. Remission, response, retention and persistence to treatment with disease-modifying agents in patients with rheumatoid arthritis: a study of harmonised Swedish, Danish and Norwegian cohorts. RMD Open. 2023;9:e003027. https:\/\/doi.org\/10.1136\/rmdopen-2023-003027.","journal-title":"RMD Open"},{"key":"3431_CR31","doi-asserted-by":"publisher","first-page":"4678","DOI":"10.1093\/rheumatology\/keac190","volume":"61","author":"SS Zhao","year":"2022","unstructured":"Zhao SS, Kearsley-Fleet L, Bosworth A, Watson K, BSRBR-RA Contributors Group, Hyrich KL. Effectiveness of sequential biologic and targeted disease modifying anti-rheumatic drugs for rheumatoid arthritis. Rheumatology (Oxford). 2022;61:4678\u201386. https:\/\/doi.org\/10.1093\/rheumatology\/keac190.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR32","unstructured":"National Institute for Health and Care Excellence (UK). Adalimumab, Etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed (TA375) [online], https:\/\/www.nice.org.uk\/guidance\/ta375"},{"key":"3431_CR33","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1002\/acr.22788","volume":"68","author":"EG Favalli","year":"2016","unstructured":"Favalli EG, Pregnolato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-year Retention Rate of First-Line Tumor necrosis factor inhibitors in rheumatoid arthritis: real-Life Data from a local Registry. Arthritis Care Res (Hoboken). 2016;68:432\u20139. https:\/\/doi.org\/10.1002\/acr.22788.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3431_CR34","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1093\/rheumatology\/keu158","volume":"53","author":"EG Favalli","year":"2014","unstructured":"Favalli EG, Biggioggero M, Marchesoni A, Meroni PL. Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. Rheumatology (Oxford). 2014;53:1664\u20138. https:\/\/doi.org\/10.1093\/rheumatology\/keu158.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR35","doi-asserted-by":"publisher","first-page":"e002842","DOI":"10.1136\/rmdopen-2022-002842","volume":"9","author":"L Leon","year":"2023","unstructured":"Leon L, Madrid-Garcia A, Lopez-Viejo P, Gonz\u00e1lez-\u00c1lvaro I, Novella-Navarro M, Freites Nu\u00f1ez D, et al. Difficult-to-treat rheumatoid arthritis (D2T RA): clinical issues at early stages of disease. RMD Open. 2023;9:e002842. https:\/\/doi.org\/10.1136\/rmdopen-2022-002842.","journal-title":"RMD Open"},{"key":"3431_CR36","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.semarthrit.2019.02.004","volume":"49","author":"M B\u00e9c\u00e8de","year":"2019","unstructured":"B\u00e9c\u00e8de M, Alasti F, Gessl I, Haupt L, Kerschbaumer A, Landesmann U, et al. Risk profiling for a refractory course of rheumatoid arthritis. Semin Arthritis Rheum. 2019;49:211\u20137. https:\/\/doi.org\/10.1016\/j.semarthrit.2019.02.004.","journal-title":"Semin Arthritis Rheum"},{"key":"3431_CR37","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1093\/rheumatology\/keac563","volume":"62","author":"A Giollo","year":"2023","unstructured":"Giollo A, Zen M, Larosa M, Astorri D, Salvato M, Calligaro A, et al. Early characterization of difficult-to-treat rheumatoid arthritis by suboptimal initial management: a multicentre cohort study. Rheumatology (Oxford). 2023;62:2083\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/keac563.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR38","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1136\/annrheumdis-2018-213378","volume":"77","author":"L Kearsley-Fleet","year":"2018","unstructured":"Kearsley-Fleet L, Davies R, De Cock D, Watson KD, Lunt M, Buch MH, et al. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Ann Rheum Dis. 2018;77:1405\u201312. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213378.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR39","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1136\/annrheumdis-2019-216539","volume":"79","author":"P Emery","year":"2020","unstructured":"Emery P, Horton S, Dumitru RB, Naraghi K, van der Heijde D, Wakefield RJ, et al. Pragmatic randomised controlled trial of very early etanercept and MTX versus MTX with delayed etanercept in RA: the VEDERA trial. Ann Rheum Dis. 2020;79:464\u201371. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216539.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR40","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2147\/OARRR.S372724","volume":"14","author":"M Leu Agelii","year":"2022","unstructured":"Leu Agelii M, Hafstr\u00f6m I, Svensson B, Ajeganova S, Forslind K, Andersson M, et al. Misdiagnosis of rheumatoid arthritis in a long-term cohort of early arthritis based on the ACR-1987 classification criteria. Open Access Rheumatol. 2022;14:187\u201394. https:\/\/doi.org\/10.2147\/OARRR.S372724.","journal-title":"Open Access Rheumatol"},{"key":"3431_CR41","doi-asserted-by":"publisher","first-page":"e743","DOI":"10.1016\/S2665-9913(23)00242-4","volume":"5","author":"S Bugatti","year":"2023","unstructured":"Bugatti S, De Stefano L, Gandolfo S, Ciccia F, Montecucco C. Autoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist. Lancet Rheumatol. 2023;5:e743\u201355. https:\/\/doi.org\/10.1016\/S2665-9913(23)00242-4.","journal-title":"Lancet Rheumatol"},{"key":"3431_CR42","doi-asserted-by":"publisher","first-page":"554","DOI":"10.55563\/clinexprheumatol\/go7g26","volume":"41","author":"L De Stefano","year":"2023","unstructured":"De Stefano L, D\u2019Onofrio B, Gandolfo S, Bozzalla Cassione E, Mauro D, Manzo A, et al. Seronegative rheumatoid arthritis: one year in review 2023. Clin Exp Rheumatol. 2023;41:554\u201364. https:\/\/doi.org\/10.55563\/clinexprheumatol\/go7g26.","journal-title":"Clin Exp Rheumatol"},{"key":"3431_CR43","doi-asserted-by":"publisher","unstructured":"Bugatti S, Schett G. Prevention of seronegative rheumatoid arthritis: an entity of its own. Lancet Rheumatol 2024 Sep 17:S2665-9913(24)00226-1. https:\/\/doi.org\/10.1016\/S2665-9913(24)00226-1","DOI":"10.1016\/S2665-9913(24)00226-1"},{"key":"3431_CR44","doi-asserted-by":"publisher","unstructured":"Takase-Minegishi K, B\u00f6hringer S, Nam JL, Kaneko Y, Behrens F, Saevarsdottir S et al. The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials. Rheumatol (Oxford) 2024 Feb 16:keae113. https:\/\/doi.org\/10.1093\/rheumatology\/keae113","DOI":"10.1093\/rheumatology\/keae113"},{"key":"3431_CR45","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/acr.23497","volume":"70","author":"AC Boer","year":"2018","unstructured":"Boer AC, Boonen A, van der Helm AHM. Is anti-citrullinated protein antibody-positive rheumatoid arthritis still a more severe Disease Than Anti-citrullinated protein antibody-negative rheumatoid arthritis? A longitudinal cohort study in rheumatoid arthritis patients diagnosed from 2000 onward. Arthritis Care Res (Hoboken). 2018;70:987\u201396. https:\/\/doi.org\/10.1002\/acr.23497.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3431_CR46","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1136\/annrheumdis-2022-222436","volume":"81","author":"S Bugatti","year":"2022","unstructured":"Bugatti S, De Stefano L, D\u2019Onofrio B, Nicrosini A, Mauric E, di Lernia M, et al. Inflammatory correlates of the Patient Global Assessment of Disease Activity vary in relation to disease duration and autoantibody status in patients with rheumatoid arthritis. Ann Rheum Dis. 2022;81:1206\u201313. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222436.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR47","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1136\/annrheumdis-2022-222264","volume":"81","author":"L De Stefano","year":"2022","unstructured":"De Stefano L, D\u2019Onofrio B, Sakellariou G, Manzo A, Montecucco C, Bugatti S. Progressive increase in time to referral and persistently severe clinical presentation over the years in autoantibody-negative patients with rheumatoid arthritis in the setting of an early arthritis clinic. Ann Rheum Dis. 2022;81:1331\u20132. https:\/\/doi.org\/10.1136\/annrheumdis-2022-222264.","journal-title":"Ann Rheum Dis"},{"key":"3431_CR48","doi-asserted-by":"publisher","first-page":"e000752","DOI":"10.1136\/rmdopen-2018-000752","volume":"4","author":"LB Nordberg","year":"2018","unstructured":"Nordberg LB, Lillegraven S, Aga AB, Sexton J, Olsen IC, Lie E, et al. Comparing the disease course of patients with seronegative and seropositive rheumatoid arthritis fulfilling the 2010 ACR\/EULAR classification criteria in a treat-to-target setting: 2-year data from the ARCTIC trial. RMD Open. 2018;4:e000752. https:\/\/doi.org\/10.1136\/rmdopen-2018-000752.","journal-title":"RMD Open"},{"key":"3431_CR49","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1093\/rheumatology\/kead378","volume":"63","author":"L De Stefano","year":"2024","unstructured":"De Stefano L, Bugatti S, Mazzucchelli I, Rossi S, Xoxi B, Bozzalla Cassione E, et al. Synovial and serum B cell signature of autoantibody-negative rheumatoid arthritis vs autoantibody-positive rheumatoid arthritis and psoriatic arthritis. Rheumatology (Oxford). 2024;63:1322\u201331. https:\/\/doi.org\/10.1093\/rheumatology\/kead378.","journal-title":"Rheumatology (Oxford)"},{"key":"3431_CR50","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41584-020-00541-7","volume":"17","author":"MH Buch","year":"2021","unstructured":"Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021;17:17\u201333. https:\/\/doi.org\/10.1038\/s41584-020-00541-7.","journal-title":"Nat Rev Rheumatol"},{"key":"3431_CR51","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2147\/POR.S399221","volume":"14","author":"GM Bruno","year":"2023","unstructured":"Bruno GM, Valentino MC, Brunetti A, Di Matteo S, Begovic I, Croce E, et al. Administrative databases and diagnostic therapeutic and assistance paths -PDTA- in the monitoring treatment of rheumatoid arthritis: the experience of ATS Pavia. Pragmat Obs Res. 2023;14:29\u201338. https:\/\/doi.org\/10.2147\/POR.S399221.","journal-title":"Pragmat Obs Res"},{"key":"3431_CR52","doi-asserted-by":"publisher","first-page":"1759720X2311941","DOI":"10.1177\/1759720X231194179","volume":"15","author":"A Zanetti","year":"2023","unstructured":"Zanetti A, Zambon A, Scir\u00e8 CA, Bugatti S, Montecucco C, Sakellariou G. Impact of csDMARDs adherence on clinical remission in patients with new-onset inflammatory arthritis: a prospective cohort study from the ELECTRA database. Ther Adv Musculoskelet Dis. 2023;15:1759720X231194179. https:\/\/doi.org\/10.1177\/1759720X231194179.","journal-title":"Ther Adv Musculoskelet Dis"}],"container-title":["Arthritis Research & Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-024-03431-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-024-03431-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:03:45Z","timestamp":1731042225000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-024-03431-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,8]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3431"],"URL":"https:\/\/doi.org\/10.1186\/s13075-024-03431-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,8]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"IRCCS Policlinico San Matteo Foundation Ethics Committee n.20070001302.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Patients and\/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient and public involvement"}},{"value":"Not applicable. The manuscript does not include identifying details of the participants that were studied.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SB reports grant\/research support from: Pfizer, and personal fees from: Alfasigma, AbbVie, Bristol-Myers Squibb, Fresenius Kabi, Lilly, Novartis, UCB. GS reports personal fees from Abbvie, Novartis, Lilly. CM reports personal fees from: Alfasigma, AbbVie, Bristol-Myers Squibb, Lilly, Galapagos, Janssen, Novartis, Pfizer, Sandoz, UCB.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}